title: Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation.
abstract: CMV disease remains a major infectious complication after allogeneic hematopoietic stem cell transplantation (HSCT). To investigate the relationship between CMV antigenemia, treatment with ganciclovir (GCV), and outcome, we retrospectively analyzed 241 consecutive patients at risk for CMV infection who underwent allogeneic HSCT. Antigenemia-guided pre-emptive strategy with GCV was used for all patients. CMV antigenemia developed in 169 patients (70.1%), and CMV disease in 18 patients (7.5%). Multivariate analysis showed that acute GVHD (grades II-IV) was the only risk factor for developing antigenemia, and acute GVHD and advanced age for CMV disease. GCV use, as well as acute GVHD and advanced age, significantly increased the risk for bacterial and fungal infection after engraftment. Those who developed CMV antigenemia had a poorer outcome than those who did not (log-rank, P=0.0269), although the development of CMV disease worsened the outcome with only borderline significance (log-rank, P=0.0526). In conclusion, detection of antigenemia proved to be a poor prognostic factor for HSCT patients, which may be attributed to a combination of factors, including CMV disease itself, the effect of treatment, and a host status that allows for reactivation of CMV. Optimal pre-emptive strategy needs to be determined.
authors.affiliation: Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan. myanada@med.nagoya-u.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Yanada
authors.forename: K
authors.initials: K
authors.lastname: Yamamoto
authors.forename: N
authors.initials: N
authors.lastname: Emi
authors.forename: T
authors.initials: T
authors.lastname: Naoe
authors.forename: R
authors.initials: R
authors.lastname: Suzuki
authors.forename: H
authors.initials: H
authors.lastname: Taji
authors.forename: H
authors.initials: H
authors.lastname: Iida
authors.forename: T
authors.initials: T
authors.lastname: Shimokawa
authors.forename: A
authors.initials: A
authors.lastname: Kohno
authors.forename: S
authors.initials: S
authors.lastname: Mizuta
authors.forename: F
authors.initials: F
authors.lastname: Maruyama
authors.forename: A
authors.initials: A
authors.lastname: Wakita
authors.forename: K
authors.initials: K
authors.lastname: Kitaori
authors.forename: K
authors.initials: K
authors.lastname: Yano
authors.forename: M
authors.initials: M
authors.lastname: Hamaguchi
authors.forename: N
authors.initials: N
authors.lastname: Hamajima
authors.forename: Y
authors.initials: Y
authors.lastname: Morishima
authors.forename: Y
authors.initials: Y
authors.lastname: Kodera
authors.forename: H
authors.initials: H
authors.lastname: Sao
authors.forename: Y
authors.initials: Y
authors.lastname: Morishita
mesh_terms: D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000453:epidemiology; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000401:mortality; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control*; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use*; D006086:Graft vs Host Disease / Q000453:epidemiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000401:mortality; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000453:epidemiology; D012008:Recurrence; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D015774:Ganciclovir